Over time, disability has become a structural factor influencing the quality of life, access to opportunities and health outcomes of those who are affected. According to the World Health Organization ...
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
Giverny Capital Asset Management, LLC, an investment management company, recently published its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.
The unique structure of PAMs has the potential to transform industries, from healthcare to robotics, by offering properties never before seen in materials science. PAMs represent a bold step forward ...